Literature DB >> 317254

Multicentre trials of praziquantel in human schistosomiasis: design and techniques.

A Davis, D H Wegner.   

Abstract

This paper outlines the experimental design and techniques used in the initial multicentre clinical experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium, S. mansoni, and S. japonicum. Trials were conducted in Brazil, Japan, the Philippines, and Zambia.Close professional cooperation between informed representatives of the manufacturers of the drug and WHO led to the use of a standard clinical trial design and agreed technical protocols, although parasitological methods of therapeutic assessment varied with the species of infecting parasite. Double-blind studies of tolerance were conducted at three different dose levels and subsequently, in Brazil and Zambia, single-blind trials of parasiticidal efficacy were carried out. The results of the various trials are reported separately.This type of close professional cooperation is a useful model for initial clinicopharmacological studies of parasiticidal drugs-an area beset with difficulties for both industry and international agencies.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 317254      PMCID: PMC2395869     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  Long-term hepatocellular effects of hycanthone and of two other anti-Schistosomal drugs in mice infected with Schistosoma mansoni.

Authors:  W H Haese; E Bueding
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

2.  The efficacy of praziquantel against cestodes in animals.

Authors:  H Thomas; R Gönnert
Journal:  Z Parasitenkd       Date:  1977-07-21

3.  A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum and S. mattheei im hamsters.

Authors:  G Webbe; C James
Journal:  Z Parasitenkd       Date:  1977-07-21

4.  Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections.

Authors:  T Ishizaki; E Kamo; K Boehme
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

5.  Carcinogenic effects of niridazole.

Authors:  H K Urman; O Bulay; D B Clayson; P Shubik
Journal:  Cancer Lett       Date:  1975-11       Impact factor: 8.679

6.  Carcinogenic effects of niridazole on rodents infected with Schistosoma mansoni.

Authors:  O Bulay; H Urman; D B Clayson; P Shubik
Journal:  J Natl Cancer Inst       Date:  1977-12       Impact factor: 13.506

7.  Mutagenicity studies with praziquantel, a new anthelmintic drug, in mammalian systems.

Authors:  L Machemer; D Lorke
Journal:  Arch Toxicol       Date:  1978-01-25       Impact factor: 5.153

8.  Hycanthone analogs: dissociation of mutagenic effects from antischistosomal effects.

Authors:  P B Hulbert; E Bueding; P E Hartman
Journal:  Science       Date:  1974-11-15       Impact factor: 47.728

9.  Mutagenicity studies with praziquantel, a new anthelmintic drug: tissue-, host-, and urine-mediated mutagenicity assays.

Authors:  J Obermeier; H Frohberg
Journal:  Arch Toxicol       Date:  1977-09-28       Impact factor: 5.153

10.  Praziquantel, a new board-spectrum antischistosomal agent.

Authors:  R Gönnert; P Andrews
Journal:  Z Parasitenkd       Date:  1977-07-21
  10 in total
  22 in total

Review 1.  Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.

Authors:  Jürg Utzinger; Jennifer Keiser; Xiao Shuhua; Marcel Tanner; Burton H Singer
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections.

Authors:  T Ishizaki; E Kamo; K Boehme
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

3.  The six diseases of WHO. Schistosomiasis: some advances.

Authors:  G Webbe
Journal:  Br Med J (Clin Res Ed)       Date:  1981-10-24

4.  Schistosomiasis: recent developments in immunology and treatment.

Authors:  D W Martin; J L Naughton; L H Smith
Journal:  West J Med       Date:  1980-07

5.  The schistosomiasis problem in the world: results of a WHO questionnaire survey.

Authors:  L S Iarotski; A Davis
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

6.  Clinical study evaluating efficacy of praziquantel in clonorchiasis.

Authors:  B G Yangco; C De Lerma; G H Lyman; D L Price
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines.

Authors:  A T Santos; B L Blas; J S Noseñas; G P Portillo; O M Ortega; M Hayashi; K Boehme
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

8.  Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium.

Authors:  A Davis; J E Biles; A M Ulrich
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

9.  Preliminary trials with praziquantel in human infections due to Schistosoma mansoni.

Authors:  N Katz; R S Rocha; A Chaves
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

Review 10.  Drugs for treating urinary schistosomiasis.

Authors:  Christine V Kramer; Fan Zhang; David Sinclair; Piero L Olliaro
Journal:  Cochrane Database Syst Rev       Date:  2014-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.